361 related articles for article (PubMed ID: 15526058)
21. Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants.
Bliss CM; Drammeh A; Bowyer G; Sanou GS; Jagne YJ; Ouedraogo O; Edwards NJ; Tarama C; Ouedraogo N; Ouedraogo M; Njie-Jobe J; Diarra A; Afolabi MO; Tiono AB; Yaro JB; Adetifa UJ; Hodgson SH; Anagnostou NA; Roberts R; Duncan CJ; Cortese R; Viebig NK; Leroy O; Lawrie AM; Flanagan KL; Kampmann B; Imoukhuede EB; Sirima SB; Bojang K; Hill AV; Nébié I; Ewer KJ
Mol Ther; 2017 Feb; 25(2):547-559. PubMed ID: 28153101
[TBL] [Abstract][Full Text] [Related]
22. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.
Bejon P; Peshu N; Gilbert SC; Lowe BS; Molyneux CS; Forsdyke J; Lang T; Hill AV; Marsh K
Clin Infect Dis; 2006 Apr; 42(8):1102-10. PubMed ID: 16575727
[TBL] [Abstract][Full Text] [Related]
23. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
McConkey SJ; Reece WH; Moorthy VS; Webster D; Dunachie S; Butcher G; Vuola JM; Blanchard TJ; Gothard P; Watkins K; Hannan CM; Everaere S; Brown K; Kester KE; Cummings J; Williams J; Heppner DG; Pathan A; Flanagan K; Arulanantham N; Roberts MT; Roy M; Smith GL; Schneider J; Peto T; Sinden RE; Gilbert SC; Hill AV
Nat Med; 2003 Jun; 9(6):729-35. PubMed ID: 12766765
[TBL] [Abstract][Full Text] [Related]
24. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.
Bejon P; Ogada E; Mwangi T; Milligan P; Lang T; Fegan G; Gilbert SC; Peshu N; Marsh K; Hill AV
PLoS One; 2007 Aug; 2(8):e707. PubMed ID: 17710125
[TBL] [Abstract][Full Text] [Related]
25. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.
Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ
PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582
[TBL] [Abstract][Full Text] [Related]
26. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.
O'Hara GA; Duncan CJ; Ewer KJ; Collins KA; Elias SC; Halstead FD; Goodman AL; Edwards NJ; Reyes-Sandoval A; Bird P; Rowland R; Sheehy SH; Poulton ID; Hutchings C; Todryk S; Andrews L; Folgori A; Berrie E; Moyle S; Nicosia A; Colloca S; Cortese R; Siani L; Lawrie AM; Gilbert SC; Hill AV
J Infect Dis; 2012 Mar; 205(5):772-81. PubMed ID: 22275401
[TBL] [Abstract][Full Text] [Related]
27. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.
Prieur E; Gilbert SC; Schneider J; Moore AC; Sheu EG; Goonetilleke N; Robson KJ; Hill AV
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):290-5. PubMed ID: 14694197
[TBL] [Abstract][Full Text] [Related]
28. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.
Bejon P; Mwacharo J; Kai O; Mwangi T; Milligan P; Todryk S; Keating S; Lang T; Lowe B; Gikonyo C; Molyneux C; Fegan G; Gilbert SC; Peshu N; Marsh K; Hill AV
PLoS Clin Trials; 2006 Oct; 1(6):e29. PubMed ID: 17053830
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
Imoukhuede EB; Berthoud T; Milligan P; Bojang K; Ismaili J; Keating S; Nwakanma D; Keita S; Njie F; Sowe M; Todryk S; Laidlaw SM; Skinner MA; Lang T; Gilbert S; Greenwood BM; Hill AV
Vaccine; 2006 Oct; 24(42-43):6526-33. PubMed ID: 16842888
[TBL] [Abstract][Full Text] [Related]
30. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.
Gilbert SC; Moorthy VS; Andrews L; Pathan AA; McConkey SJ; Vuola JM; Keating SM; Berthoud T; Webster D; McShane H; Hill AV
Vaccine; 2006 May; 24(21):4554-61. PubMed ID: 16150517
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
32. A Prime/Boost PfCS14K
Vijayan A; Mejías-Pérez E; Espinosa DA; Raman SC; Sorzano COS; Zavala F; Esteban M
Clin Vaccine Immunol; 2017 May; 24(5):. PubMed ID: 28298290
[TBL] [Abstract][Full Text] [Related]
33. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
[TBL] [Abstract][Full Text] [Related]
34. Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area.
Bejon P; Kai OK; Mwacharo J; Keating S; Lang T; Gilbert SC; Peshu N; Marsh K; Hill AV
Eur J Immunol; 2006 Aug; 36(8):2264-72. PubMed ID: 16856208
[TBL] [Abstract][Full Text] [Related]
35. Prime-boost vectored malaria vaccines: progress and prospects.
Hill AV; Reyes-Sandoval A; O'Hara G; Ewer K; Lawrie A; Goodman A; Nicosia A; Folgori A; Colloca S; Cortese R; Gilbert SC; Draper SJ
Hum Vaccin; 2010 Jan; 6(1):78-83. PubMed ID: 20061802
[TBL] [Abstract][Full Text] [Related]
36. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees.
Schneider J; Langermans JA; Gilbert SC; Blanchard TJ; Twigg S; Naitza S; Hannan CM; Aidoo M; Crisanti A; Robson KJ; Smith GL; Hill AV; Thomas AW
Vaccine; 2001 Sep; 19(32):4595-602. PubMed ID: 11535306
[TBL] [Abstract][Full Text] [Related]
37. Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naïve volunteers: a pilot study.
Stanisic DI; Fink J; Mayer J; Coghill S; Gore L; Liu XQ; El-Deeb I; Rodriguez IB; Powell J; Willemsen NM; De SL; Ho MF; Hoffman SL; Gerrard J; Good MF
BMC Med; 2018 Oct; 16(1):184. PubMed ID: 30293531
[TBL] [Abstract][Full Text] [Related]
38. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group.
Stoute JA; Slaoui M; Heppner DG; Momin P; Kester KE; Desmons P; Wellde BT; Garçon N; Krzych U; Marchand M
N Engl J Med; 1997 Jan; 336(2):86-91. PubMed ID: 8988885
[TBL] [Abstract][Full Text] [Related]
39. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
Sheehy SH; Duncan CJ; Elias SC; Choudhary P; Biswas S; Halstead FD; Collins KA; Edwards NJ; Douglas AD; Anagnostou NA; Ewer KJ; Havelock T; Mahungu T; Bliss CM; Miura K; Poulton ID; Lillie PJ; Antrobus RD; Berrie E; Moyle S; Gantlett K; Colloca S; Cortese R; Long CA; Sinden RE; Gilbert SC; Lawrie AM; Doherty T; Faust SN; Nicosia A; Hill AV; Draper SJ
Mol Ther; 2012 Dec; 20(12):2355-68. PubMed ID: 23089736
[TBL] [Abstract][Full Text] [Related]
40. Vaccines for preventing malaria.
Graves P; Gelband H
Cochrane Database Syst Rev; 2003; (1):CD000129. PubMed ID: 12535387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
